Pfizer/Boehringer’s Spiriva Captures 10% Share Of New Prescriptions
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer and Boehringer Ingelheim's chronic obstructive pulmonary disease therapy Spiriva (tiotropium) has a 10% share of new prescriptions.